The Data, Evaluation, and Coordination Center (DECC) for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT)

项目摘要 尽管美国人口的总体死亡率和癌症发病率有所下降，但癌症护理的差异 主要存在于某些群体中。一个关键的障碍是， 缺乏采用科学严谨的方法和实施战略的专门努力 来增加他们在临床试验中的比例代表性。连接代表性不足的人口 临床试验（CIP 2CT）计划旨在实施和评估多层次和文化定制的外展 以及教育干预，这将增加临床试验中代表性不足人群的增加。到 为了支持CNOP 2CT计划，我们建议成为数据、评估和协调中心（DECC） 支持数据和评估活动，并协调学习协作，以减轻 癌症差异的障碍。具体而言，我们将与UMP 2CT U 01研究人员合作， 与参与的NCI工作人员和其他利益相关者（如需要）一起开展以下活动：1） 通过科学领导建立有效和高效的行政程序和基础设施， 组织流程、治理结构、有效监督和业务程序， 最佳的沟通，协作，协调，和传播的CNOP 2CT研究，2）促进 并协调整个CIP 2CT项目的数据收集和管理，以促进证据生成 方法和工具的快速传播，3）组织和促进有关方案的合作努力 评估，参与和沟通，以及4）在领导和协调方面促进学习合作 trans-P2CT研究。 我们是唯一的定位是DECC为CIP 2 T利用强大的跟踪记录：（i）实施 健康公平中心和联盟（例如Odedina博士是NCI CRCHD U 54 CaRE 2健康公平中心的MPI 并联系MPI为新授予的国防部iCCaRE黑人联盟）;（ii）领导 统计和数据管理协调中心在癌症试验中的努力（例如，马约是统计和数据 肿瘤临床试验联盟（Alliance）管理中心，包括介入性和 NCORP赠款）;（ii）领先的标准化和互操作性的实践和研究（例如，马约已经 促进NCI术语服务开发工作和数据协调工作的一部分， NCATS临床数据健康（CD 2 H））。此外，我们有强有力的机构优先事项， 利用现有的基础设施和资源支持P2CT的使命。

Project Summary Despite the decline in overall mortality and incidence of cancer in the US population, disparities in cancer care still largely exist within certain groups. One key barrier causing the lack of proportional representation of these groups is the lack of dedicated efforts employing scientific rigorous approaches and implementation strategies for increasing their proportional representation in clinical trials. The Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) program aims to implement and evaluate multilevel and culturally tailored outreach and education interventions that will increase the accrual of underrepresented populations in clinical trials. To support the CUSP2CT program, we are proposing to be the Data, Evaluation, and Coordination Center (DECC) to support the data and evaluation activities and coordinate a learning collaborative towards mitigating the key barriers of cancer disparity. Specifically, we will collaborate with the CUSP2CT U01 investigators and interact with involved NCI staff members and with other stakeholders, as needed, to carry out the following activities: 1) establish effective and efficient administrative processes and infrastructure through scientific leadership, organizational processes, governance structure, effective oversight and operational procedures to achieve optimal communication, collaboration, coordination, and dissemination of the CUSP2CT research, 2) facilitate and coordinate data collection and management across the CUSP2CT program to facilitate evidence generation and rapid dissemination of methods and tools, 3) organize and facilitate collaborative efforts on program evaluation, engagement, and communication, and 4) foster a learning collaborative in leading and coordinating trans-CUSP2CT research. We are uniquely positioned to be the DECC for CUSP2T leveraging strong track record in: (i) implementing health equity centers and consortia (e.g. Dr. Odedina is MPI on NCI CRCHD U54 CaRE2 Health Equity Center and contact MPI for a newly awarded Department of Defense iCCaRE for Black Men Consortium); (ii) leading statistics and data management coordinating center effort in cancer trials (e.g., Mayo is the Statistics and Data Management Center of the Alliance for Clinical Trials in Oncology (Alliance) including both interventional and NCORP grants); (ii) leading standardization and interoperability for practice and research (e.g., Mayo has been contributing to the NCI Terminology Service Development Effort and part of the data harmonization efforts in the NCATS Clinical Data to Health (CD2H)). Additionally, we have strong institutional priorities aligning with CUSP2CT with existing infrastructure and resources supporting the CUSP2CT mission.